Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

15.4%

4 terminated out of 26 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results75% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (3)
Early P 1 (1)
P 1 (11)
P 2 (6)
P 3 (2)

Trial Status

Completed12
Active Not Recruiting4
Terminated4
Recruiting2
Not Yet Recruiting1
Withdrawn1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT07246863Phase 2Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT06403436Phase 1Active Not Recruiting

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

NCT02568267Phase 2Active Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT04705818Phase 2Completed

Combining Epigenetic And Immune Therapy to Beat Cancer.

NCT07098988Phase 2Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT03445858Early Phase 1Completed

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

NCT06059547Phase 2Active Not Recruiting

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

NCT05147272Phase 1TerminatedPrimary

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

NCT05752552Phase 1Active Not RecruitingPrimary

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT03760952Completed

Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

NCT03061305Terminated

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

NCT04538625Phase 3Completed

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

NCT06277804Phase 1Not Yet RecruitingPrimary

A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor

NCT04892043Phase 1TerminatedPrimary

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT05357898Phase 1TerminatedPrimary

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT05400265Phase 1CompletedPrimary

Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor

NCT04084951Phase 1CompletedPrimary

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

NCT05666635Phase 1UnknownPrimary

Study of LTC004 in Subjects With Advanced Malignant Tumors

NCT03303365Not ApplicableCompleted

Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence

NCT01791595Phase 1CompletedPrimary

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Scroll to load more

Research Network

Activity Timeline